Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression

(2016) Saby George et al.   JAMA Oncology

Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma

(2015) Hideyuki Takahashi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

(2015) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

PD-1 regulates extrathymic regulatory T-cell differentiation

(2014) Xiufen Chen et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism

(2014) Zhidong Yan et al.   EXPERIMENTAL CELL RESEARCH

Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma

(2014) Ian-James Malm et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer

(2014) Zhiqiang Guo et al.   PLoS One

Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients

(2013) H-B Jie et al.   BRITISH JOURNAL OF CANCER

Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

(2013) S. Lyford-Pike et al.   CANCER RESEARCH

Staphylococcus aureusconvert neonatal conventional CD4+T cells into FOXP3+ CD25+ CD127lowT cells via the PD-1/PD-L1 axis

(2013) Hardis Rabe et al.   IMMUNOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4+Foxp3+ Regulatory T Cells and PD-1/PD-L1/L2 Expression

(2012) L. J. Hatam et al.   CLINICAL CANCER RESEARCH

Immunological modulation by 1α,25-dihydroxyvitamin D3 in patients with squamous cell carcinoma of the head and neck

(2012) David D. Walker et al.   CYTOKINE

Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response

(2012) Anna-Maria A. De Costa et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck

(2011) Anna-Maria A. De Costa et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma

(2011) Tatiana Salles de Souza Malaspina et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Use of α,25-Dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma

(2010) Jarrett E. Walsh et al.   HUMAN IMMUNOLOGY

Tumor Secretion of VEGF Induces Endothelial Cells to Suppress T cell Functions Through the Production of PGE2

(2010) Jennifer K. Mulligan et al.   JOURNAL OF IMMUNOTHERAPY

Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions

(2009) Jennifer K. Mulligan et al.   HUMAN IMMUNOLOGY

Use of Carcinogen-induced Premalignant Oral Lesions in a Dendritic Cell-based Vaccine to Stimulate Immune Reactivity Against Both Premalignant Oral Lesions and Oral Cancer

(2008) M. Rita I. Young   JOURNAL OF IMMUNOTHERAPY